Merck's Keytruda Meets Study Goals as Advanced Melanoma Treatment

Merck said cancer drug Keytruda met its two primary endpoints in a phase III study as a first-line treatment for patients with advanced melanoma.



from WSJ.com: US Business http://ift.tt/1DTsykI

via IFTTT